Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 23, 2023 (4 years ago)

Finasteride Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Finasteride Tablets, USP, 5 mg, packaged in: a) 30-count bottles (NDC 68788-6976-3); b) 90-count bottles (NDC 68788-6976-9), Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703.

Affected NDCs 68788-6976-03 68788-6976-09

Compare with the code on your package — it is the most precise check available.

Drug: Finasteride

Recalling firm
Preferred Pharmaceuticals, Inc.
NDC code
68788-6976-3
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0516-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Finasteride recalls

See all
Class II · Moderate risk

Finasteride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0733-90 D-0477-2023
Class II · Moderate risk

Finasteride Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-090-10 D-0392-2023
Class II · Moderate risk

Finasteride Tablets USP 1 mg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 71713-096-90 D-0391-2023
Class II · Moderate risk

Finasteride Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-089-10 D-0390-2023

Other recalls by Preferred Pharmaceuticals, Inc.

All 2023 recalls
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026
Class II · Moderate risk

Ibuprofen Tablets

Failed Impurities/Degradation Specifications - at 18-month Stability testing

Ongoing Impurity / degradation Preferred Pharmaceuticals, Inc. NDC 68788-9110-03 D-0647-2024